MedPath

XURIDEN

These highlights do not include all the information needed to use XURIDEN safely and effectively. See full prescribing information for XURIDEN. XURIDEN® (uridine triacetate) oral granulesInitial U.S. Approval: 2015

Approved
Approval ID

40606ca9-4f14-45b7-8632-fc2d17d11a2e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 11, 2022

Manufacturers
FDA

Wellstat Therapeutics Corporation

DUNS: 785233024

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

uridine triacetate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69468-152
Application NumberNDA208169
Product Classification
M
Marketing Category
C73594
G
Generic Name
uridine triacetate
Product Specifications
Route of AdministrationORAL
Effective DateDecember 16, 2019
FDA Product Classification

INGREDIENTS (5)

uridine triacetateActive
Quantity: 951 mg in 1 g
Code: 2WP61F175M
Classification: ACTIB
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1A
Classification: IACT
ORANGE JUICEInactive
Code: 5A9KE2L9L3
Classification: IACT
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
ETHYLCELLULOSE, UNSPECIFIEDInactive
Code: 7Z8S9VYZ4B
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

XURIDEN - FDA Drug Approval Details